Search
for
Sort by
Research 271–300 of 1000+
- Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Treatments for alopecia areata: a network meta-analysis
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
- Determination of serum 25-hydroxyvitamin D levels in patients with alopecia areata and their comparison with levels in healthy controls: A cross-sectional study
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Quality of Life in Alopecia Areata: A Study of 60 Cases
- Evaluating the Causal Relationship Between Human Blood Metabolites and the Susceptibility to Alopecia Areata
- MiR-199a-3p Regulates the PTPRF/β-Catenin Axis in Hair Follicle Development: Insights into the Pathogenic Mechanism of Alopecia Areata
- Off-Label Treatment of Alopecia Areata—Retrospective Study
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata
- Effect of minoxidil combined with triamcinolone acetonide on alopecia areata by microneedle injection
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Evaluation of the Awareness, Beliefs, and Psychological Impact of Patients with Alopecia Areata in Makkah City, Saudi Arabia
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- Alopecia Areata: Current and Emerging Therapies
- Predictive Metagenomic Profiling, Urine Metabolomics, and Human Marker Gene Expression as an Integrated Approach to Study Alopecia Areata
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Health‐related quality of life of adult and adolescent patients living with alopecia areata in Australia
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial